DOCSLIB.ORG

Targets for Cancer Prevention and Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targets for Cancer Prevention and Therapy Charles Rodolphe Brupbacher Stiftung Targets for Cancer Prevention and Therapy Preisverleihung und Wissenschaftliches Symposium 2009 Charles Rodolphe Brupbacher Stiftung Targets for Cancer Prevention and Therapy Edited by Holger Moch Alexander Knuth Paul Kleihues Ponte Press Targets for Cancer Prevention and Therapy H. Moch, A. Knuth, P. Kleihues (Eds.) Ponte Press Bochum ISBN 978-3-920328-54-6 Impressum Charles Rodolphe Brupbacher Stiftung Wissenschaftliches Sekretariat c/o Medizinisches Dekanat der Universität Zürich Pestalozzistr. 3/5 CH-8091 Zürich Schweiz Layout: Sarah Frey Druck: Druckerei Fröhlich, Zollikon 5 Impressum Inhalt Contents Charles Rodolphe Brupbacher Preis für Krebsforschung 2009 Charles Rodolphe Brupbacher Prize for Cancer Research 2009 Programm der Preisverleihung 9 Program of the Award Ceremony 9 Nubia Muñoz 11 Nubia Muñoz 11 Laudatio 11 Laudatio 11 CV und Publikationen 12 CV and Publications 12 Festvortrag 15 Lecture 15 Sir Richard Peto 19 Sir Richard Peto 19 Laudatio 19 Laudation 19 CV und Publikationen 20 CV and Publications 20 Festvortrag 23 Award Lecture 23 Bisherige Preisträger 25 Previous Laureates 25 Symposium 2009 27 Symposium 2009 27 Programm 28 Program 28 Abstracts der Referenten 30 Abstracts of Invited Speakers 30 Poster Abstracts 50 Poster Abstracts 50 Charles Rodolphe Brupbacher Stiftung 113 Charles Rodolphe Brupbacher Foundation 113 Die Stiftung 114 The Foundation 114 Charles Rodolphe Brupbacher 115 Charles Rodolphe Brupbacher 115 Stiftungsrat 117 Foundation Board 117 Wissenschaftlicher Beirat 118 Scientific Advisory Board 118 Stiftungsadresse 119 Address of the Foundation 119 Adressen 120 Address List 120 Index 123 Index 123 Inhalt / Contents 6 Preisverleihung Charles Rodolphe Brupbacher Preis für Krebsforschung 2009 Award Ceremony Charles Rodolphe Brupbacher Prize for Cancer Research 2009 7 Charles Rodolphe Brupbacher Preis für Krebsforschung 2009 Charles Rodolphe Brupbacher Preis Charles Rodolphe Brupbacher Prize für Krebsforschung 2009 for Cancer Research 2009 Die Stiftung verleiht alle zwei Jahre den Charles Rodolphe Biennially, the Foundation bestows the Charles Rodolphe Brupbacher Preis für Krebsforschung an Wissenschaftler, die auf Brupbacher Prize for Cancer Research upon a scientist who has dem Gebiet der Grundlagenforschung hervorragende Leistungen made extraordinary contributions to basic oncological research. erbracht haben. Die Preisverleihung findet statt im Rahmen eines The Prize ceremony takes place within the framework of a internationalen wissenschaftlichen Symposiums, an dem auch der Scientific Symposium, which includes the Charles Rodolphe öffentliche Charles Rodolphe Brupbacher Vortrag gehalten wird. Brupbacher Public Lecture. Der Preis für das Jahr 2009 wird verliehen an: The recipients of the 2009 Prize are: Nubia Muñoz, Lyon, Frankreich Nubia Muñoz, Lyon, France Sir Richard Peto, Oxford, Vereinigtes Königreich Sir Richard Peto, Oxford, United Kingdom Charles Rodolphe Brupbacher Prize for Cancer Research 2009 8 Charles Rodolphe Brupbacher Preis für Krebsforschung Universitätsspital Zürich, Grosser Hörsaal Nord, Frauenklinikstrasse 10, 8091 Zürich Donnerstag, 12. Februar 2009, um 17:00 Uhr Begrüssung Prof. Dr. Klaus W. Grätz, Dekan, Präsident des Wissenschaftlichen Beirats Prof. Dr. Andreas Fischer, Rektor der Universität Zürich Frédéric Chopin, Fantasie Impromptu Laudationes Prof. Dr. Nubia Muñoz Prof. Sir Richard Peto durch Prof. Dr. D. Maxwell Parkin Prof. Dr. Paul Kleihues Preisverleihung Frau Frédérique Brupbacher, Präsidentin der Stiftung Robert Schumann, Kinderszenen, Träumerei und Wichtige Begebenheit Referate Prof. Dr. Nubia Muñoz Franz Liszt, Vallée d` Obermann Prof. Sir Richard Peto Ludwig van Beethoven, Sonate Op. 2 Nr. 3 in C-Dur Allegro con brio Schlussworte Prof. Dr. Klaus W. Grätz Apéro 9 Programm der Preisverleihung Charles Rodolphe Brupbacher Prize for Cancer Research University Hospital Zurich, Lecture Hall Nord, Frauenklinikstrasse 10, 8091 Zurich Thursday, February 12th, 2009, 17:00 pm Introduction Prof. Dr. Klaus W. Grätz, Dean, President of the Scientific Board Prof. Dr. Andreas Fischer, Rector of University of Zurich Frédéric Chopin, Fantasie Impromptu Laudationes Prof. Dr. Nubia Muñoz Prof. Sir Richard Peto by Prof. Dr. D. Maxwell Parkin Prof. Dr. Paul Kleihues Awards Mrs. Frédérique Brupbacher, President of the Foundation Robert Schumann, Kinderszenen, Träumerei und Wichtige Begebenheit Lectures Prof. Dr. Nubia Muñoz Franz Liszt, Vallée d`Obermann Prof. Sir Richard Peto Ludwig van Beethoven, Sonata Op. 2 Nr. 3 in C-Dur Allegro con brio Final address Prof. Dr. Klaus W. Grätz Apéro Program of the Award Ceremony 10 Laudatio Charles Rodolphe Brupbacher Foundation D. Maxwell Parkin Dr Muñoz career began as a pathologist in her native Colombia, The in the department of her mentor Professor Pelayo Correa. Her Charles Rodolphe Brupbacher Prize for Cancer Research 2009 professional interest soon moved to the field of epidemiology, is awarded to however, and she received her training in the discipline at the US National Cancer Institute, and Johns Hopkins University. Her research first focussed on gastric cancer, with a series Dr. Nubia Muñoz of studies following up the observations of Lauren on the differing aetiology and geographic distribution of intestinal for her contributions and diffuse types of gastric carcinoma. This work took her to to the epidemiology of cancer causation by chronic infections, the International Agency for Research on Cancer (IARC) in in particular the etiology of cervical cancer. Lyon in the 1970’s, where she worked with Dr Callum Muir and Dr Nick Day, before taking charge of her own research unit in the mid 1980’s. Her main research interest at that time was in oesophageal cancer, and particularly the reasons for its striking geographic distribution. Work with Nick Day in Iran in The President The President of the Foundation of the Scientific Board the pre-revolutionary days was followed by a series of studies in high-risk areas of China, including an elaborate intervention study with micronutrients (β-carotene, riboflavin and zinc). Her group also conducted a series of studies on the epidemiology of Mrs. Frédérique Brupbacher Prof. Dr. Klaus W. Grätz hepatocellular carcinoma in Asia and Africa. But, even by this time, Dr Muñoz had an ongoing interest in cancer of the uterine cervix. The epidemiology of this cancer had been much studied in the 1960’s and 70’s, and, in a review in 1976, Dr Munoz concluded “The evidence suggests that a venereally transmitted virus and/or hormonal factors are involved in the etiology of cervical cancer”. This was before the work of Prof Harald zur Hausen in the early 1980’s, detecting the presence of human papilloma virus in tumour tissue (for which he was later awarded the Nobel prize). At that time, there was some scepticism concerning the role of HPV infection. In an important review, published in 1988, Dr Munoz wrote: “The human papillomavirus has emerged over the past decade as the leading candidate to be the sexually transmitted aetiological factor in cervical cancer. Although it appears that papillomavirus types 16 and 18 are associated with a higher risk of advanced cervical neoplasia, most of the evidence comes from studies which do not satisfy basic epidemiological requirements, and are 11 Charles Rodolphe Brupbacher Prize for Cancer Research 2009 therefore difficult to interpret……. On the basis of the existing Dr. Nubia Muñoz studies, one is forced to conclude that, while experimental data suggest an oncogenic potential for HPV, the epidemiological evidence implicating it as a cause of cervical neoplasia is still rather limited”. Curicculum vitae and Publications From her unit at IARC Dr Muñoz began to lead a major programme of research. This began with an international series of case-control studies using modern laboratory techniques that demonstrated that HPV infection by certain genotypes of HPV is one the strongest cancer risk factors ever found. Subsequent work produced precise estimates of relative risks that permitted defining the HPV genotypes that had to be targeted for prevention. At the same time, the International Biological Study of Cervical Cancer (IBSCC) identified the HPV types associated with tumours occurring in different parts of the world. By 1999, it was possible to assert that HPV infection should considered a necessary cause of cervix cancer. Dr Muñoz convinced the IARC that the role of HPVs should be evaluated in one of the authoritative Monograph series on carcinogenicity evaluation. In 1995, HPVs 16 and 18 were classified as “Group 1, Human Place of birth Cali, Colombia Carcinogens”. This monograph was an important stimulus Home address 24, Quai Fulchiron to the development of HPV tests with the aim of improving 69005 Lyon (France) traditional cervical cancer screening, which had hitherto relied Telephone: +33 478429021 upon cytology examination using the Pap test. Perhaps even more Current position Emeritus Professor, National Cancer importantly, the Monograph gave pharmaceutical companies the Institute, Bogota, Colombia evidence needed to take the financial risks in developing and Visiting Scientist, Catalan Institute of field-testing candidate HPV vaccines. The end result is that Oncology, Barcelona, Spain there are now two new fronts for cervical cancer prevention: HPV vaccination and improved screening with HPV tests, all Graduate and Postgraduate Education originated from Dr Muñoz’ vigorous and relentless leadership on the epidemiology front
Load more

Recommended publications
  • What Statistics Can and Can't Tell Us About Ourselves | the New Yorker
    What Statistics Can and Canʼt Tell Us About Ourselves | The New Yorker 2019-09-04, 1005 Books September 9, 2019 Issue What Statistics Can and Can’t Tell Us About Ourselves In the era of Big Data, we’ve come to believe that, with enough information, human behavior is predictable. But number crunching can lead us perilously wrong. By Hannah Fry September 2, 2019 https://www.newyorker.com/magazine/2019/09/09/what-statistics…3&utm_medium=email&utm_term=0_c9dfd39373-f791742ba3-42227231 Page 1 of 15 What Statistics Can and Canʼt Tell Us About Ourselves | The New Yorker 2019-09-04, 1005 Making individual predictions from collective characteristics is a risky business. Illustration by Ben Wiseman 0"00 / 23"27 Audio: Listen to this article. To hear more, download Audm for iPhone or Android. arold Eddleston, a seventy-seven-year-old from Greater Manchester, H was still reeling from a cancer diagnosis he had been given that week https://www.newyorker.com/magazine/2019/09/09/what-statistics…3&utm_medium=email&utm_term=0_c9dfd39373-f791742ba3-42227231 Page 2 of 15 What Statistics Can and Canʼt Tell Us About Ourselves | The New Yorker 2019-09-04, 1005 when, on a Saturday morning in February, 1998, he received the worst possible news. He would have to face the future alone: his beloved wife had died unexpectedly, from a heart attack. Eddleston’s daughter, concerned for his health, called their family doctor, a well-respected local man named Harold Shipman. He came to the house, sat with her father, held his hand, and spoke to him tenderly.
    [Show full text]
  • Note for the Record: Consultation on Clinical Trial Design for Ebola Virus Disease (EVD)
    Note for the record: Consultation on Clinical Trial Design for Ebola Virus Disease (EVD) A group of independent scientific experts was convened by the WHO for the purpose of evaluating a proposed clinical trial design for investigational therapeutics for Ebola virus disease (EVD) during the current outbreak, 26 May 2018 Experts Sir Michael Jacobs (Chair), Dr Rick Bright, Dr Marco Cavaleri, Dr Edward Cox, Dr Natalie Dean, Dr William Fischer, Dr Thomas Fleming, Dr Elizabeth Higgs, Dr Peter Horby, Dr Philip Krause, Dr Trudie Lang, Dr Denis Malvy, Sir Richard Peto, Dr Peter Smith, Dr Marianne Van der Sande, Dr Robert Walker, Dr David Wohl, Dr Alan Young. There are many pathogens for which there is no proven specific treatment. For some pathogens, there are treatments that have shown promising safety and activity in the laboratory and in relevant animal models but have not yet been evaluated fully for safety and efficacy in humans. In the context of an outbreak characterized by high mortality rates, the Monitored Emergency Use of Unregistered Interventions (MEURI)1 framework is a means to provide access to promising but unproven investigational therapies, but is not a means to evaluate reliably whether these compounds are actually beneficial to patients or not. In light of the current Ebola Zaire DRC outbreak with a high case fatality rate, the WHO convened an independent expert panel to evaluate investigational therapeutics for MEURI use2, and that panel affirmed the importance of moving to appropriate clinical trials as soon as possible. Against this background, a clinical trial design has been proposed with a view to generating reliable evidence about safety and efficacy.
    [Show full text]
  • Sir Richard Doll, Epidemiologist – a Personal Reminiscence with a Selected Bibliography
    British Journal of Cancer (2005) 93, 963 – 966 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com Obituary Sir Richard Doll, epidemiologist – a personal reminiscence with a selected bibliography The death of Richard Doll on 24 July 2005 at the age of 92 after a short illness ended an extraordinarily productive life in science for which he received widespread recognition, including Fellowship of The Royal Society (1966), Knighthood (1971), Companionship of Honour (1996), and many honorary degrees and prizes. He is unique, however, in having seen both universal acceptance of his work demonstrating smoking as the main cause of the most common fatal cancer in the world and the relative success of strategies to reduce the prevalence of the habit. In 1950, 80% of the men in Britain smoked but this has now declined to less than 30%. Richard Doll qualified in medicine at St Thomas’ Hospital in 1937, but his epidemiological career began after service in the Second World War when he worked with Francis Avery Jones at the Central Middlesex Hospital on occupational factors in the aetiology of peptic ulceration. The completeness of Doll’s tracing of previously surveyed men so impressed Tony Bradford Hill that he offered him a post in the MRC Statistical Research Unit to investigate the causes of lung cancer. For the representations of Percy Stocks (Chief Medical Officer to the Registrar General) and Sir Ernest Kennaway had prevailed against the then commonly held view that the marked rise in lung cancer deaths in Britain since 1900 was due only to improved diagnosis.
    [Show full text]
  • Whoseжlegacyжwillжreadersж Celebrateжthisжyear?
    BMJ GROUP AWARDS •ЖReviewЖtheЖshortlistsЖforЖallЖcategoriesЖatЖhttp://bit.ly/aUWoE5 Sir George Alleyne •ЖListenЖtoЖtheЖawardsЖlaunchЖpodcastЖatЖbmj.com/podcasts A highly respected figure in global health, George Alleyne has played LIFETIME ACHIEVEMENT AWARD a large part in tackling HIV and non-communicable disease and WhoseЖlegacyЖwillЖreadersЖ is an energetic promoter of health equality across the world. Currently the chancellor of the University celebrateЖthisЖyear? of the West Indies, Sir George is also the former director of the Pan Annabel FerrimanЖintroducesЖthisЖyear’sЖawardЖandЖ American Health Organization. Adrian O’DowdЖrevealsЖtheЖshortlistedЖcandidates Born in Barbados, he graduated in medicine from the University When Belgian senator Marleen Temmerman called on women in Belgium of the West Indies in 1957 and to refuse to have sex with their partners until the country’s politicians continued his postgraduate ended eight months of wrangling and formed a government, few people studies in the United Kingdom and effect on national economies. in the UK had heard of her. But readers of the BMJ were in the know and the United States. During more Sir George has served on various unsurprised. than a decade of original research, committees including the For Professor Temmerman, an obstetrician and gynaecologist, had he produced 144 publications in scientific and technical advisory won the BMJ Group’s Lifetime Achievement Award last April. In that case, scientific journals, which qualified committee of the World Health it was not for suggesting a “crossed leg strike” to end political deadlock him at just 40 years of age to be Organization Tropical Research (a solution advocated by the women of Greece in Aristophanes’ play appointed professor of medicine Programme and the Institute of Lysistrata) but for her services to women’s health in Belgium and Kenya.
    [Show full text]
  • A Cancer Control Interview With: Sir Richard Peto
    CANCER CONTROL PLANNING A CANCER CONTROL INTERVIEW WITH: SIR RICHARD PETO Sir Richard Peto is Professor of Medical Statistics & Epidemiology at the University of Oxford, United Kingdom. In 1975, he set up the Clincial Trial Service Unit in the Medical Sciences Division of Oxford University, of which he and Rory Collins are now co-directors. Professor Peto's work has included studies of the causes of cancer in general, and of the effects of smoking in particular, and the establishment of large-scale randomised trials of the treatment of heart disease, stroke, cancer and a variety of other diseases. He has been instrumental in introducing combined "meta-analyses" of results from related trials that achieve uniquely reliable assessment of treatment effects. He was elected a Fellow of the Royal Society of London in 1989, and was knighted (for services to epidemiology and to cancer prevention) in 1999. Cancer Control: How should the global target of a 25% reduction country would die before they were 70; now it is 18%. in premature mortality from non-communicable diseases (NCDs) by 2025 be interpreted? Cancer Control: NCD advocates place great emphasis on the Sir Richard Peto: I would define “premature death” as death relative burden of non-communicable diseases compared with during the middle age range of 35 to 69 years. It’s not that communicable diseases. Are they right to do so? deaths after 70 don’t matter – I’m after 70 myself and I’m Sir Richard Peto: I don’t like these things that say “More still enjoying life – but if you are going to do things to reduce people die from NCDs than from communicable disease and NCDs then it is going to be to reduce NCD mortality in your therefore NCDs are more important”.
    [Show full text]
  • A Kernel Log-Rank Test of Independence for Right-Censored Data
    A kernel log-rank test of independence for right-censored data Tamara Fern´andez∗ Arthur Gretton University College London University College London [email protected] [email protected] David Rindt Dino Sejdinovic University of Oxford University of Oxford [email protected] [email protected] November 18, 2020 Abstract We introduce a general non-parametric independence test between right-censored survival times and covariates, which may be multivariate. Our test statistic has a dual interpretation, first in terms of the supremum of a potentially infinite collection of weight-indexed log-rank tests, with weight functions belonging to a reproducing kernel Hilbert space (RKHS) of functions; and second, as the norm of the difference of embeddings of certain finite measures into the RKHS, similar to the Hilbert-Schmidt Independence Criterion (HSIC) test-statistic. We study the asymptotic properties of the test, finding sufficient conditions to ensure our test correctly rejects the null hypothesis under any alternative. The test statistic can be computed straightforwardly, and the rejection threshold is obtained via an asymptotically consistent Wild Bootstrap procedure. Extensive simulations demonstrate that our testing procedure generally performs better than competing approaches in detecting complex non-linear dependence. 1 Introduction Right-censored data appear in survival analysis and reliability theory, where the time-to-event variable one is interested in modelling may not be observed fully, but only in terms of a lower bound. This is a common occurrence in clinical trials as, usually, the follow-up is restricted to the duration of the study, or patients may decide to withdraw from the study.
    [Show full text]
  • STATISTICAL SCIENCE Volume 31, Number 4 November 2016
    STATISTICAL SCIENCE Volume 31, Number 4 November 2016 ApproximateModelsandRobustDecisions..................James Watson and Chris Holmes 465 ModelUncertaintyFirst,NotAfterwards....................Ingrid Glad and Nils Lid Hjort 490 ContextualityofMisspecificationandData-DependentLosses..............Peter Grünwald 495 SelectionofKLNeighbourhoodinRobustBayesianInference..........Natalia A. Bochkina 499 IssuesinRobustnessAnalysis.............................................Michael Goldstein 503 Nonparametric Bayesian Clay for Robust Decision Bricks ..................................................Christian P. Robert and Judith Rousseau 506 Ambiguity Aversion and Model Misspecification: An Economic Perspective ................................................Lars Peter Hansen and Massimo Marinacci 511 Rejoinder: Approximate Models and Robust Decisions. .James Watson and Chris Holmes 516 Filtering and Tracking Survival Propensity (Reconsidering the Foundations of Reliability) .......................................................................Nozer D. Singpurwalla 521 On Software and System Reliability Growth and Testing. ..............FrankP.A.Coolen 541 HowAboutWearingTwoHats,FirstPopper’sandthendeFinetti’s?..............Elja Arjas 545 WhatDoes“Propensity”Add?...................................................Jane Hutton 549 Reconciling the Subjective and Objective Aspects of Probability ...............Glenn Shafer 552 Rejoinder:ConcertUnlikely,“Jugalbandi”Perhaps..................Nozer D. Singpurwalla 555 ChaosCommunication:ACaseofStatisticalEngineering...............Anthony
    [Show full text]
  • Asymptotically Efficient Rank Invariant Test Procedures Author(S): Richard Peto and Julian Peto Source: Journal of the Royal Statistical Society
    Asymptotically Efficient Rank Invariant Test Procedures Author(s): Richard Peto and Julian Peto Source: Journal of the Royal Statistical Society. Series A (General), Vol. 135, No. 2 (1972), pp. 185-207 Published by: Wiley for the Royal Statistical Society Stable URL: http://www.jstor.org/stable/2344317 Accessed: 21-04-2017 17:23 UTC JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact [email protected]. Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at http://about.jstor.org/terms Royal Statistical Society, Wiley are collaborating with JSTOR to digitize, preserve and extend access to Journal of the Royal Statistical Society. Series A (General) This content downloaded from 171.65.37.237 on Fri, 21 Apr 2017 17:23:40 UTC All use subject to http://about.jstor.org/terms J. R. Statist. Soc. A, 185 (1972), 135, Part 2, p. 185 Asymptotically Efficient Rank Invariant Test Procedures By RICHARD PETO AND JULIAN PETO Radcliffe Infirmary, Institute of Psychiatry Oxford University University of London [Read before the ROYAL STATISTICAL SOCIETY on Wednesday, January 19th, 1972, the President Professor G. A. BARNARD in the Chair] SUMMARY Asymptotically efficient rank invariant test procedures for detecting differences between two groups of independent observations are derived. These are generalized to test between two groups of independent censored observations, to test between many groups of observations, and to test between groups after allowance for the effects of concomitant variables.
    [Show full text]
  • EVIDENCE BASED MEDICINE.Pdf (PDF, 8.01MB)
    RARE BOOKS LIB. &!:bM The University of Sydney Copyright and use of this thesis This thesis must be used in accordance with the provisions of the Copyright Act 1968. Reproduction of material protected by copyright may be an infringement of copyright and copyright owners may be entitled to take legal action against persons who infringe their copyright. Section 51 (2) of the Copyright Act permits an authorized officer of a university library or archives to provide a copy (by communication or otherwise) of an unpublished thesis kept in the library or archives, to a person who satisfies the authorized officer that he or she requires the reproduction for the purposes of research or study. The Copyright Act grants the creator of a work a number of moral rights, specifically the right of attribution, the right against false attribution and the right of integrity. You may infringe the author's moral rights if you: • fail to acknowledge the author of this thesis if you quote sections from the work • attribute this thesis to another author • subject this thesis to derogatory treatment which may prejudice the author's reputation For further information contact the University's Director of Copyright Services Telephone: 02 9351 2991 e-mail: [email protected] Evidence Based Medicine: Evolution, Revolution, or Illusion? A philosophical examination of the foundations of Evidence Based Medicine Adam LaCaze A thesis submitted for the degree of Doctor of Philosophy Department of Philosophy, The University of Sydney, 2009 ii Evidence based medicine: Evolution, Revolution, or Illusion? Preface Declaration of Originality. The content of this thesis represents my own original contribution.
    [Show full text]
  • Design and Analysis Issues in Family-Based Association
    Emerging Challenges in Statistical Genetics Duncan Thomas University of Southern California Human Genetics in the Big Science Era • “Big Data” – large n and large p and complexity e.g., NIH Biomedical Big Data Initiative (RFA-HG-14-020) • Large n: challenge for computation and data storage, but not conceptual • Large p: many data mining approaches, few grounded in statistical principles • Sparse penalized regression & hierarchical modeling from Bayesian and frequentist perspectives • Emerging –omics challenges Genetics: from Fisher to GWAS • Population genetics & heritability – Mendel / Fisher / Haldane / Wright • Segregation analysis – Likelihoods on complex pedigrees by peeling: Elston & Stewart • Linkage analysis (PCR / microsats / SNPs) – Multipoint: Lander & Green – MCMC: Thompson • Association – TDT, FBATs, etc: Spielman, Laird – GWAS: Risch & Merikangas – Post-GWAS: pathway mining, next-gen sequencing Association: From hypothesis-driven to agnostic research Candidate pathways Candidate Hierarchical GWAS genes models (ht-SNPs) Ontologies Pathway mining MRC BSU SGX Plans Objectives: – Integrating structural and prior information for sparse regression analysis of high dimensional data – Clustering models for exposure-disease associations – Integrating network information – Penalised regression and Bayesian variable selection – Mechanistic models of cellular processes – Statistical computing for large scale genomics data Targeted areas of impact : – gene regulation and immunological response – biomarker based signatures – targeting
    [Show full text]
  • Read the 2019 Issue of Observatory
    GREEN TEMPLETON COLLEGE, UNIVERSITY OF OXFORD 2019 GREEN TEMPLETON LECTURES Mapping 2,000 years of approaches to leadership RESEARCH Avoiding premature death, FinTech and the global commons GLOBAL ENGAGEMENT New faces, relaunched website and revitalised social media THIS YEAR AT GREEN TEMPLETON Welcome to Observatory, a new magazine providing a flavour of life in college over the past year. High among our list of values is our diversity. With close to 80 countries represented in our student body, we have enjoyed celebrations of the Chinese New Year and the US thanksgiving, a South American Living and barbecue, an evening of Indian music, and working in the performances of our African choir this college is always stir the emotions. Our ethos of care applies not only to people but also a source This year for to the environment. Mondays in Green Templeton are the first time, the now meat-free; a decision taken by fellows, students of great University has and staff determined to emphasise the Green in Green recruited more Templeton! This aim includes reducing single-use plastics, pride female than male buying more locally produced food and addressing fuel students. Green consumption in our properties. Templeton was Living and working in this college is a source of already ahead of the curve with 56% of our students being great pride as is evident from the pages that follow. We female. As a graduate college, some of our students arrive are ready to embrace the opportunity provided as the having already had work experience and, with an average Radcliffe Observatory Quarter is being established as entry age of 29, some come with partners and children.
    [Show full text]
  • CTSU Clinical Trial Service Unit & Epidemiological Studies Unit
    Clinical Trial Service Unit & Epidemiological Studies Unit CTSU University of Oxford Nuffield Department of Clinical Medicine 30 November 2012 CTSU, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK Tel: +44-(0)-1865-743743 Fax: +44-(0)-1865-743985 Website: www.ctsu.ox.ac.uk Dear WHO Expert Committee: I am writing to support the inclusion of fixed dose combination therapy (also known as “polypill” therapy) for secondary prevention of cardiovascular disease in the World Health Organization’s (WHO) Model List of Essential Medicines. I have over the past 30 years been a co-principal investigator in many large-scale trials and meta-analyses of drugs that reduce recurrence rates after occlusive stroke or a myocardial infarct. All these drugs are now off-patent, and together they offer substantial benefits to those who have already suffered such an event, but they are not widely enough used in low and middle-income countries, partly because affordable co-formulations are not conveniently and affordably available To achieve maximum effect, treatments to reduce the global burden of cardiovascular disease must be strategically deployed to reach a diverse population. The availability and use of fixed dose combination therapy for secondary prevention of cardiovascular disease will overcome many of the barriers that currently prevent sufficient treatment, including poor adherence, unaffordable cost and inadequate prescription of medication. Different expert panels, including the WHO and the Combination Pharmacotherapy and Public Health Research Working Group, have recognized the potential value of fixed dose combination therapy for secondary prevention of cardiovascular disease. I agree with and support the recommendation to add fixed dose combination therapy to the WHO Model List of Essential Medicines for secondary prevention of cardiovascular disease based on its relative affordability, availability, and effectiveness.
    [Show full text]